BioCurate Pty Ltd is a collaboration between the University of Melbourne and Monash University, two of Australia's top universities for biomedical and pharmaceutical research.
Biomedical Research Victoria (BioMedVic) is the peak body for the organisations that make up this internationally-recognised research community, providing a collective voice for advocacy and a structure for promoting collaboration and innovation.
The BioMelbourne Network is a not-for-profit membership association for organisations engaged in biotechnology, medical technology and health innovation in the state of Victoria. Their role is to foster links between companies, research organisations, financial markets and government, creating an environment for greater collaboration and prosperity.
Bionic Vision Technologies is dedicated to developing effective and innovative implantable retinal prostheses (“bionic eyes”) for patients who have lost vision due to Retinitis Pigmentosa. Their approach is based on proven technology and data from early prototype investigations that form part of a core product pipeline.
Bioregulatory Consulting (BRC) provides a specialised regulatory and development service to the biotechnology and pharmaceutical industries. BRC is a privately held company, based in Melbourne, which was founded in February 2002.
Bioshares is Australia's leading biotech stock report. Bioshares delivers independent investment research to investors on Australian biotech, pharmaceutical and healthcare companies.
BiotechBridge facilitates your business development across Australia, Israel and Latin America with our market insight, business cultural understanding capacity and organic network capital in industry, government, R&D and commercialisation centres.
Blue Curve are medical device design and safety engineering experts, working exclusively with medical devices. From lab bench to market, having a specialist focus allows Blue Curve to go deep with your product.
At Boehringer Ingelheim, the purpose is simply to ‘Make More Health’ - for patients, people and community.
Brandwood CKC has a global reputation for excellence in regulatory, quality systems and commercialisation consultancy earned through service to international health innovators for more than 20 years.
Brien Holden Vision Institute believes that sight is a fundamental right for everyone, everywhere. The Institute develops new solutions for vision care, especially refractive error, and work to eliminate vision impairment and avoidable blindness, thereby improving quality of life for people in need and helping to reduce disability and poverty.
Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
Cancer Therapeutics CRC (CTx) is in the business of finding cures for cancer.
Cancer Trials Australia (CTA) is a member-based, clinical trial network organisation.
Captixbio is a pioneering Australian company developing innovative medical technologies to optimise the therapeutic impact of cell therapies.
Caretech Services combine procedural packaging with the intelligence to ensure patient safety while generating the RWD necessary for effective disease control and pharmaceutical monitoring.
Carina Biotech is a spin-out company from the CRC for Cell Therapy Manufacturing (CTM@CRC Ltd). Carina serves as an IP development and commercialisation vehicle for T-cell immunotherapy related technologies, in particular, chimeric antigen receptor T cell (CAR-T) technologies.
Australia’s leading regenerative medicine researchers have come together in a coordinated, collaborative fashion to support the creation of CCRM Australia.
Celgene is a global biopharmaceutical company committed to changing the course of human health through bold pursuits in science, life-enhancing therapies and a promise to always put patients first.
Cell Therapies Pty Ltd (CTPL) is a leading cGMP manufacturer and distributor of cellular therapies. CTPL has operated TGA regulated cell processing facilities from Melbourne Australia, through strong clinical ties across multiple therapeutic areas. The company's facilities and capabilities are commercially available on a fee-for-service basis and have been used by the world’s leading cellular therapies companies.